Efficacy and safety of intralesional 5-fluorouracil in treatment of warts
DOI:
https://doi.org/10.66344/jpad.v28i3.1267Keywords:
Wart, 5-fluorouracil, intralesionalAbstract
Objective To determine the efficacy and safety to intralesional 5-flourouracil in the treatment of common warts.
Methods This interventional study was conducted in the Department of Dermatology, PGMI/AMC/Lahore General Hospital Lahore from October, 2016 to July, 2017. 40 patients with warts were treated with intralesional 5-FU (0.1ml/cm2 of 5-FU, 50mg/ml), at the base of each wart. Injections were repeated every two weeks, maximum for six injections. Patients followed fortnightly upto 2 months after last injection for efficacy and safety.
Results Overall 30 (75%) patients (of all types of warts) showed excellent results (maximum six injections) and remained clear on follow-up after 2 months of last treatment session. Localized irritation and pain were the major side effects encountered in all patients.
Conclusion Intralesional 5-FU is an effective and safe treatment for treatment of common, plantar and genital warts.
References
1. Li X, Yu J, Thomas S, Lee K, Soyer HP. Clinical and dermoscopic features of common warts. J Eur Acad Dermatol Venereol. 2017;31:e308-e310.
2. Haribakhti PB, Macwan R. Viral skin infections. In: Valia RG, Valia AR, editors. IADVL Textbook and Atlas of Dermatology 2nd edn. Mumbai: Bhalani Publishing House; 2001. P.303-9.
3. Gibbs S, Harvey I, sterling JC, Stark R. Local treatments for cutaneous warts. Cochrane Database Syst Rev. 2003;(3):Cd 001781.
4. Lemon JA, Benton EC. Verrucas. Guidelines for management. Am J Clin Dermatol. 2000;1:143-9.
5. Kubeyinje EP. Evaluation of the efficacy and safely 0.05% tretinoin cream in the treatment of lane warts in Arab Children. J Dermatol Treat. 1996;7:21-2.
6. Pringle WM, Helms DC. Treatment of Plantar warts by blunt dissection. Arch Dermatol. 1973;108:79-82.
7. Buckley D. Cryosurgery treatment of Plantar warts. Int Med J. 2000;93:140-3.
8. Streling JC, Handfield-Jones S, Hudson PM. Guidliness for the management of cutaneous warts. Br J Dermatol. 2001;144:4-11.
9. Fox PA, Tung Mr. Human Papilloma virus: burden of illness and treatment cost considerations. Am J Clin Dermatol. 2005;6:365-81.
10. Gnoshal K, Jacob ST, An alternative molecular mechanism of action of 5-fleorouracil, a Potent anticancer drug. Broche Pharmacol. 1997;53:1569-75.
11. Bunney MH. The treatment, of Plan warts with 5-fluorouracil. Br J Dermatol. 1973;89:96-7.
12. Iscimen A, Aydemir EH, Goksugar N, Engin B. Intralesional 5-fluorouracil, lidocaine and epinephrine mixture for the treatment of verrucae: a prospective placebo controlled, single-blind randomized study. J Eur Acad Dermatol Venereol. 2004;18:445-8.
13. Swinehart JM, Sperling M, Philips S, Kraus S, Gordon S, McCarty JM et al. Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminate: A phase 3 clinical study. Arch Dermatol. 1997;133:67-73.
14. Yazdanfar A, Farshchian M, Fereydoonnejad M, Farshchian M. Treatment of common warts with an intralesional mixture of 5-fluorouracil, lidocaine, and epinephrine: a prospective placebo-controlled, double-blind randomized trial. Dermatol Surg. 2008;34:656-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Tahir Kamal, Farhana Ahmad, Usma Iftikhar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
